Every material Form 8-K Acadia Pharmaceuticals filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Acadia Pharmaceuticals reported third quarter 2025 total revenue of $278.6 million, up 11% from a year earlier, and net income of $71.8 million, or $0.42 per diluted share, compared with $32.8 million a year earlier. The company raised its 2025 NUPLAZID net product sales guidance and lowered the top of its DAYBUE sales range while narrowing it; the net income gain includes a one-time tax benefit.
Q3 2025 total revenue of $278.6 million, up 11% year-over-year; NUPLAZID sales $177.5 million and DAYBUE sales $101.1 million
Q3 net income of $71.8 million ($0.42 diluted) vs. $32.8 million ($0.20) in Q3 2024, including a one-time tax benefit tied to the One Big Beautiful Bill Act
2025 total revenue guidance of $1.070 to $1.095 billion, vs. prior $1.045 to $1.095 billion; NUPLAZID guidance raised to $685 to $695 million from $665 to $690 million
Cash, cash equivalents and investment securities of $847.0 million at September 30, 2025
Acadia Pharmaceuticals said director Daniel B. Soland resigned from its Board and from his role as Chair of the Nominating and Corporate Governance Committee, effective October 30, 2025. The filing states the resignation was not due to any dispute or disagreement with the company or the Board about its operations, policies or practices.
Daniel B. Soland notified the Board of his resignation on October 28, 2025.
Resignation is effective October 30, 2025, and covers his Board seat and his committee membership and chair role.
The filing says the resignation involved no dispute or disagreement with the company or the Board.
Acadia Pharmaceuticals reported second-quarter 2025 total revenue of $264.6 million, up 9% from a year earlier, driven by growth in NUPLAZID and DAYBUE sales. Net income fell to $26.7 million, or $0.16 per share, because the effective tax rate rose, and the company raised the low end of its 2025 NUPLAZID sales guidance and its total revenue guidance.
Total revenue was $264.6 million, up 9% from $242.0 million in the second quarter of 2024.
Net income was $26.7 million, or $0.16 per diluted share, versus $33.4 million, or $0.20 per share, a year earlier.
Full-year 2025 total revenue guidance low end raised to $1.045 billion from $1.030 billion; NUPLAZID net sales guidance low end raised to $665 million; other guidance reiterated.
Top-line results from the COMPASS PWS Phase 3 study of ACP-101 are expected in early Q4 2025.
On May 16, 2025, a U.S. District Court in Delaware ruled in Acadia's favor on both infringement and validity in its '721 formulation patent case over Nuplazid (pimavanserin) against Aurobindo and MSN. The same week, Acadia agreed to a 12-year, two-month lease for about 52,771 square feet in Princeton, New Jersey, and will end its current 502 Carnegie Center lease after the new lease begins.
Court ruling date: May 16, 2025, in the U.S. District Court for the District of Delaware, covering both infringement and validity arguments
Defendants in the patent case: Aurobindo Pharma Limited and its affiliate, and MSN Laboratories Private Ltd. and its affiliate
210 Lease: about 52,771 square feet, term of 12 years and 2 months, commencing no later than January 1, 2026, with first-year payment of $1,899,756
Maximum landlord contribution of $5,277,100 for improvements, with a possible $2,638,550 supplemental contribution repayable with 8.00% interest
Acadia Pharmaceuticals reported first quarter 2025 total revenues of $244.3 million, up 19% from a year earlier, and net income of $19.0 million, or $0.11 per diluted share, compared with $16.6 million, or $0.10 per share, in the first quarter of 2024. The company reiterated most of its full year 2025 guidance but raised its R&D expense range to $330 million to $350 million, citing the accelerated timing of the ACP-101 Phase 3 study.
Total revenues of $244.3 million, up 19%; NUPLAZID net product sales of $159.7 million, up 23%; DAYBUE net product sales of $84.6 million, up 11%
Net income of $19.0 million, or $0.11 per diluted share, versus $16.6 million, or $0.10 per share, a year earlier
Full year 2025 R&D expense guidance raised to $330 million to $350 million from $310 million to $330 million; other guidance reiterated
Cash, cash equivalents and investment securities of $681.6 million at March 31, 2025, down from $756.0 million at December 31, 2024, after $98.8 million in payments to Neuren
Acadia Pharmaceuticals reported fourth-quarter and full-year 2024 results, with total revenue of $957.8 million for the year and net income of $226.5 million, compared with a net loss of $61.3 million in 2023. The full-year profit includes a one-time $146.5 million gain from the sale of a rare pediatric disease priority review voucher. The company also gave full-year 2025 total revenue guidance of $1.03 billion to $1.095 billion.
Full-year 2024 net product sales were $957.8 million, up 32%, with NUPLAZID at $609.4 million and DAYBUE at $348.4 million.
Fourth-quarter 2024 net income was $143.7 million, or $0.86 per diluted share, compared with $45.8 million, or $0.28 per share, a year earlier.
2025 guidance calls for total revenue of $1.03 billion to $1.095 billion, with NUPLAZID net sales of $650 million to $690 million and DAYBUE net sales (U.S. only) of $380 million to $405 million.
Cash, cash equivalents and investment securities were $756.0 million at December 31, 2024, up from $438.9 million a year earlier.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Acadia Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →